{"entity":{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","aka":[],"tldr":"Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.","summary":"Emily Bergsland is Professor of Medicine and Associate Director for Education at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist focused on gastroenteropancreatic neuroendocrine tumours, she chaired the Alliance A021202 trial of pazopanib versus placebo in progressive carcinoid tumours and co-authors national neuroendocrine tumour treatment guidelines. Her papers include NCCN guidance on the management of advanced gastroenteropancreatic neuroendocrine tumours, a review of systemic therapies for advanced gastrointestinal carcinoid tumours and the A021202 trial report. Her record links to lutetium-177 dotatate, somatostatin receptor 2 and VEGF-directed therapy, and she leads UCSF's cancer education programmes.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2","vegf"],"drugs":["lutathera"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jnccn","hematology-oncology-clinics-of-north-america"],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Associate Director for Education, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Neuroendocrine tumours","Gastrointestinal oncology","Clinical trials"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland"}],"papers":[{"title":"Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors","journal":"Journal of the National Comprehensive Cancer Network","year":2025,"url":"https://doi.org/10.6004/jnccn.2025.5012","doi":"10.6004/jnccn.2025.5012"},{"title":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors","journal":"Hematology/Oncology Clinics of North America","year":2016,"url":"https://doi.org/10.1016/j.hoc.2015.09.002","doi":"10.1016/j.hoc.2015.09.002"},{"title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202)","journal":"Journal of Clinical Oncology (ASCO Annual Meeting abstract)","year":2019,"url":"https://doi.org/10.1200/JCO.2019.37.15_suppl.4005","doi":"10.1200/JCO.2019.37.15_suppl.4005"}]},"route":"/people/emily-bergsland/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"journal":[{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","route":"/journals/hematology-oncology-clinics-of-north-america/"},{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/"}]}}